These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 35363908)

  • 1. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Younossi ZM; Paik JM; Al Shabeeb R; Golabi P; Younossi I; Henry L
    Hepatology; 2022 Nov; 76(5):1423-1437. PubMed ID: 35363908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatologists' Awareness and Knowledge of NAFLD and the Familiarity with Renaming NAFLD to MAFLD.
    Alem SA; Fouad Y; AbdAllah M; Attia D; Kamal I; Said E; Gomaa A; Abd-Elsalam SM; Gaber Y
    Endocr Metab Immune Disord Drug Targets; 2024; 24(12):1445-1453. PubMed ID: 36306455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
    Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
    Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.
    Lee H; Lee HW; Kim SU; Chang Kim H
    Clin Transl Gastroenterol; 2022 Jan; 13(1):e00435. PubMed ID: 35080508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study.
    Lee SM; Cho GJ; Wi WY; Norwitz ER; Koo BK; Lee J; Jung YM; Kwak SH; Park CW; Jun JK; Joo SK; Oh MJ; Kim W; Park JS
    Hepatol Int; 2023 Apr; 17(2):367-376. PubMed ID: 36542262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
    Ng CH; Huang DQ; Nguyen MH
    Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017-2018.
    Zhang Y; Zhang M; Jiang S; Hu H; Wang X; Yu F; Huang Y; Liang Y
    Cancer Causes Control; 2024 Sep; 35(9):1271-1282. PubMed ID: 38764062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JGH Open; 2024 Oct; 8(10):. PubMed ID: 39403113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.